Radiation-induced brain injury in patients with meningioma treated with proton or photon therapy
Tóm tắt
Radiation therapy is often used to treat meningioma with adverse features or when unresectable. Proton therapy has advantages over photon therapy in reducing integral dose to the brain. This study compared the incidence of radiological and clinical adverse events after photon versus proton therapy in the treatment of meningioma. A retrospective review was conducted on patients with meningioma treated with proton or photon therapy at two high-volume tertiary cancer centers. Patients with a history of prior radiation therapy (RT) or less than 3 months of follow-up were excluded. Post-RT imaging changes were categorized into abnormal T2 signal intensities (T2 changes) or abnormal T1 post-contrast and T2 signal intensities (T1c+T2 changes) on magnetic resonance imaging (MRI). Clinical outcomes of adverse events and survival were compared between the proton and photon therapies. Among the total of 77 patients, 38 patients received proton therapy and 39 patients received photon therapy. The median age at diagnosis was 55 years and median follow-up was 2.2 years. No significant differences in symptomatic adverse events were observed between the two groups: grade ≥ 2 adverse events were seen in 4 (10.5%) patients in the proton group and 3 (7.7%) patients in the photon group (p = 0.67). The 2-year cumulative incidences of T2 changes were 38.3% after proton therapy and 47.7% after photon therapy (p = 0.53) and the 2-year cumulative incidences of T1c+T2 changes were 26.8% after proton therapy and 5.3% after photon therapy (p = 0.02). One patient experienced grade ≥ 4 adverse event in each group (p = 0.99). Estimated 2-year progression-free survival was 79.5% (proton therapy 76.0% vs. photon therapy 81.3%, p = 0.66) and 2-year overall survival was 89.7% (proton therapy 86.6% vs. photon therapy 89.3%, p = 0.65). Following RT, high rates of T2 changes were seen in meningioma patients regardless of treatment modality. Proton therapy was associated with significantly higher rates of T1c+T2 changes compared with photon therapy, but severe adverse events were uncommon in both groups and survival outcomes were comparable between the two groups. Future studies will aim at correlating the MRI changes with models that can be incorporated into RT planning to avoid toxicity.
Tài liệu tham khảo
Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99:307–314
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62
Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, Vecht C (2008) Meningioma. Crit Rev Oncol Hematol 67:153–171
Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57:1088–1095 (discussion 1088-95)
Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA, Riley K (2008) Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus 24:E3
Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT Jr, Barker FG 2nd (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64:56–60 (discussion 60)
Park HJ, Kang HC, Kim IH, Park SH, Kim DG, Park CK, Paek SH, Jung HW (2013) The role of adjuvant radiotherapy in atypical meningioma. J Neurooncol 115:241–247
Komotar RJ, Iorgulescu JB, Raper DM, Holland EC, Beal K, Bilsky MH, Brennan CW, Tabar V, Sherman JH, Yamada Y, Gutin PH (2012) The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg 117:679–686
al-Mefty O, Kersh JE, Routh A, Smith RR, (1990) The long-term side effects of radiation therapy for benign brain tumors in adults. J Neurosurg 73:502–512
van Nieuwenhuizen D, Klein M, Stalpers LJ, Leenstra S, Heimans JJ, Reijneveld JC (2007) Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. J Neurooncol 84:271–278
Kallio M, Sankila R, Hakulinen T, Jääskeläinen J (1992) Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 31:2–12
Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, Shaw EG (1998) Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 73:936–942
Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL (1997) Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39:427–436
Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL (1985) Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62:18–24
Murray FR, Snider JW, Bolsi A, Lomax AJ, Walser M, Kliebsch U, Schneider RA, Weber DC (2017) Long-term clinical outcomes of pencil beam scanning proton therapy for benign and non-benign intracranial meningiomas. Int J Radiat Oncol Biol Phys 99:1190–1198
Madani I, Lomax AJ, Albertini F, Trnková P, Weber DC (2015) Dose-painting intensity-modulated proton therapy for intermediate- and high-risk meningioma. Radiat Oncol 10:72
Sanford NN, Yeap BY, Larvie M, Daartz J, Munzenrider JE, Liebsch NJ, Fullerton B, Pan E, Loeffler JS, Shih HA (2017) Prospective, randomized study of radiation dose escalation with combined proton-photon therapy for benign meningiomas. Int J Radiat Oncol Biol Phys 99:787–796
Paganetti H, van Luijk P (2013) Biological considerations when comparing proton therapy with photon therapy. Semin Radiat Oncol 23:77–87
Haas-Kogan D, Indelicato D, Paganetti H, Esiashvili N, Mahajan A, Yock T, Flampouri S, MacDonald S, Fouladi M, Stephen K, Kalapurakal J, Terezakis S, Kooy H, Grosshans D, Makrigiorgos M, Mishra K, Poussaint TY, Cohen K, Fitzgerald T, Goindi V, Liu A, Michalski J, Mirkovic D, Mohan R, Perkins S, Wong K, Vikram B, Buchsbaum J, Kun L (2018) National cancer institute workshop on proton therapy for children: considerations regarding brainstem injury. Int J Radiat Oncol Biol Phys 101:152–168
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published May 28, 2009 (v4.03: June 14, 2010). U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute. Accessed 20 July 2019.
Bojaxhiu B, Ahlhelm F, Walser M, Placidi L, Kliebsch U, Mikroutsikos L, Morach P, Bolsi A, Lomax T, Pica A, Weber DC (2018) Radiation necrosis and white matter lesions in pediatric patients with brain tumors treated with pencil beam scanning proton therapy. Int J Radiat Oncol Biol Phys 100:987–996
Bahn E, Bauer J, Harrabi S, Herfarth K, Debus J, Alber M (2020) Late contrast enhancing brain lesions in proton-treated patients with low-grade glioma: clinical evidence for increased periventricular sensitivity and variable RBE. Int J Radiat Oncol Biol Phys 107:571–578
Eulitz J, Troost EGC, Raschke F, Schulz E, Lutz B, Dutz A, Löck S, Wohlfahrt P, Enghardt W, Karpowitz C, Krause M, Lühr A (2019) Predicting late magnetic resonance image changes in glioma patients after proton therapy. Acta Oncol 58:1536–1539
Roberts KW, Wan Chan Tseung HS, Eckel LJ, Harmsen WS, Beltran C, Laack NN (2019) Biologic dose and imaging changes in pediatric brain tumor patients receiving spot scanning proton therapy. Int J Radiat Oncol Biol Phys 105:664–673
Niyazi M, Niemierko A, Paganetti H, Söhn M, Schapira E, Goldberg S, Adams J, Kim V, Oh KS, Hwang WL, Lu HM, Belka C, Busse PM, Loeffler JS, Shih HA (2020) Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model. Radiother Oncol 142:154–161
Acharya S, Robinson CG, Michalski JM, Mullen D, DeWees TA, Campian JL, Chundury A, Bottani B, Hallahan DE, Bradley JD, Huang J (2018) Association of 1p/19q codeletion and radiation necrosis in adult cranial gliomas after proton or photon therapy. Int J Radiat Oncol Biol Phys 101:334–343
Bronk JK, Guha-Thakurta N, Allen PK, Mahajan A, Grosshans DR, McGovern SL (2018) Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma. Clin Transl Radiat Oncol 9:30–34
Dworkin M, Mehan W, Niemierko A, Kamran SC, Lamba N, Dietrich J, Martinez-Lage M, Oh KS, Batchelor TT, Wen PY, Loeffler JS, Shih HA (2019) Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol 142:69–77
Ludmir EB, Mahajan A, Paulino AC, Jones JY, Ketonen LM, Su JM, Grosshans DR, McAleer MF, McGovern SL, Lassen-Ramshad YA, Adesina AM, Dauser RC, Weinberg JS, Chintagumpala MM (2019) Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol 21:686–695
Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, Dicker AP (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76:S20–S27
Weber DC, Lomax AJ, Rutz HP, Stadelmann O, Egger E, Timmermann B, Pedroni ES, Verwey J, Mirabell R, Goitein G, Swiss Proton Users Group (2004) Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. Radiother Oncol 71(3):251–258
McPherson CM, Warnick RE (2004) Results of contemporary surgical management of radiation necrosis using frameless stereotaxis and intraoperative magnetic resonance imaging. J Neurooncol 68:41–47
Shaw E, Scott C, Souhami L, Dinapoli R, Bahary JP, Kline R, Wharam M, Schultz C, Davey P, Loeffler J, Del Rowe J, Marks L, Fisher B, Shin K (1996) Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90–05). Int J Radiat Oncol Biol Phys 34:647–654
Korytko T, Radivoyevitch T, Colussi V, Wessels BW, Pillai K, Maciunas RJ, Einstein DB (2006) 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors. Int J Radiat Oncol Biol Phys 64:419–424
Sneed PK, Mendez J, Vemer-van den Hoek JG, Seymour ZA, Ma L, Molinaro AM, Fogh SE, Nakamura JL, McDermott MW (2015) Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg 123:373–386
Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65:499–508
Indelicato DJ, Bradley JA, Rotondo RL, Nanda RH, Logie N, Sandler ES, Aldana PR, Ranalli NJ, Beier AD, Morris CG, Mendenhall NP (2018) Outcomes following proton therapy for pediatric ependymoma. Acta Oncol 57:644–648
Vogel J, Carmona R, Ainsley CG, Lustig R (2019) The promise of proton therapy for central nervous system malignancies. Neurosurgery 84:1000–1010
Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP (2018) Intermediate-risk meningioma: initial outcomes from NRG oncology RTOG 0539. J Neurosurg 129:35–47
Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman A, Galvin J, Fogh SE, Youssef E, Deb N, Kwok Y, Robinson CG, Shu HK, Fisher B, Panet-Raymond V, McMillan WG, de Groot JF, Zhang P, Mehta MP (2020) High-risk meningioma: initial outcomes from NRG oncology/RTOG 0539. Int J Radiat Oncol Biol Phys 106:790–799
Baumert BG, Norton IA, Lomax AJ, Davis JB (2004) Dose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions. Int J Radiat Oncol Biol Phys 60:1314–1324
Arvold ND, Niemierko A, Broussard GP, Adams J, Fullerton B, Loeffler JS, Shih HA (2012) Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma. Int J Radiat Oncol Biol Phys 83:e495-500
Borg A, Ekanayake J, Mair R, Smedley T, Brew S, Kitchen N, Samandouras G, Robertson F (2013) Preoperative particle and glue embolization of meningiomas: Indications, results, and lessons learned from 117 consecutive patients. Neurosurgery 73(2):244–251 (discussion ons252)
Rosen CL, Ammerman JM, Bank SLN, WO, (2002) Outcome analysis of preoperative embolization in cranial base surgery. Acta Neurochir (Wien) 144:1157–1164
Kai Y, Hamada J, Morioka M, Yano S, Todaka T, Ushio Y (2002) Appropriate interval between embolization and surgery in patients with meningioma. AJNR Am J Neuroradiol 23:139–142
Probst EN, Grzyska U, Westphal M, Zeumer H (1999) Preoperative embolization of intracranial meningiomas with a fibrin glue preparation. AJNR Am J Neuroradiol 20:1695–1702
Bendszus M, Monoranu CM, Schütz A, Nölte I, Vince GH, Solymosi L (2005) Neurologic complications after particle embolization of intracranial meningiomas. AJNR AM J Neuroradiol 26:1413–1419
Carli DFM, Sluzewski M, Beute GN, van Rooij WJ (2010) Complications of particle embolization of meningiomas: frequency, risk factors, and outcome. AJNR Am J Neuroradiol 31:152–154
Shah A, Choudhri O, Jung H, Li G (2015) Preoperative endovascular embolization of meningiomas: update on therapeutic options. Neurosurg Focus 38:E7
Dziuk TW, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS, Lu H, Carpenter LS, Chiu JK (1998) Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 37:177–188
Pettersson-Segerlind J, Orrego A, Lönn S, Mathiesen T (2011) Long-term 25-year follow-up of surgically treated parasagittal meningiomas. World Neurosurg 76:564–571
Giantsoudi D, Grassberger C, Craft D, Niemierko A, Trofimov A, Paganetti H (2013) Linear energy transfer-guided optimization in intensity modulated proton therapy: feasibility study and clinical potential. Int J Radiat Oncol Biol Phys 87:216–222
Peeler CR, Mirkovic D, Titt U, Blanchard P, Gunther J, Mahajan A, Mohan R, Grosshans DR (2016) Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. Radiother Oncol 121:395–401